Letter: Calcineurin inhibitor level reduction during treatment with sofosbuvir in liver transplanted patients

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 4, 2014, Pages 405-

  Vukotic, R ^a   Morelli, M C ^a   Pinna, A D ^a   Margotti, M ^a   Foschi, F G ^b   Loggi, E ^a   Bernardi, M ^a   Andreone, P ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UOC di Pediatria e Neonatologia AUSL Della Romagna   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RIBAVIRIN; SOFOSBUVIR; TACROLIMUS;

ADULT; CLINICAL ARTICLE; COMPASSIONATE USE; DRUG DOSE INCREASE; HEPATITIS C; HUMAN; LETTER; LIVER TRANSPLANTATION; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; URIDINE MONOPHOSPHATE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84904420819     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12853     Document Type: Letter

References (2)

1. Mathias A, Cornpropst M, Clemons D, Denning J, Symonds WT,. No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporine A or tacrolimus in healthy volunteers (abstract 1869). 63rd Meeting of the AASLD. Boston, MA; 2012.
2. Koff RS,. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014; 39: 478-87.